在慢性非癌症疼痛中对阿片类药物使用障碍的概念分析,使用罗杰的进化方法
Evans F Kyei1, Lingling Zhang1, Suzanne Leveille1
1Manning College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, Massachusetts.
概括
慢性非癌症疼痛 (CNCP) 中的阿片类药物使用障碍 (OUD) 是复杂的,受疼痛,阿片类药物使用和心理健康的影响. 在CNCP中解决OUD对于改善患者的治疗结果至关重要,需要共同的政策努力.
科学领域:
- 疼痛管理和成研究研究
- 公共卫生与公共政策
背景情况:
- 阿片类药物使用障碍 (OUD) 在治疗慢性非癌症疼痛 (CNCP) 方面存在重大挑战.
- 了解OUD在CNCP群体中的多面性质对于有效的治疗策略至关重要.
研究的目的:
- 在慢性非癌症疼痛 (CNCP) 患者中全面检查阿片类药物使用障碍 (OUD) 的先例,属性和后果.
- 在CNCP管理的背景下探索与OUD相关的相互关联的概念.
主要方法:
- 进行了系统的文献审查,分析了2015年至2022年间发表的22篇文章.
- 搜索的数据库包括CINAHL,MEDLINE,PsycINFO和PubMed,以确保广泛的研究范围.
- 包括的文章进行了批判性审查,以确定与CNCP中OUD相关的关键主题和概念.
主要成果:
- 在CNCP中OUD的先例包括功能改善的目标,阿片类药物处方,社会因素和心理健康状况.
- 确定的主要属性是慢性疼痛,非癌症疼痛以及阿片类药物使用,滥用或滥用模式.
- 后果包括功能障碍,健康风险增加,心理痛苦,社会困难和经济负担.
结论:
- 认识到OUD在CNCP中的复杂性对于提高患者护理和结果至关重要.
- 医疗保健系统,监管机构和专业组织之间的合作政策制定对于安全的疼痛管理是必要的.
- 实施基于证据的实践和政策建议可以优化疼痛管理,促进CNCP患者的福祉.
相关概念视频
Analgesia and Pain Management
584
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
584
Opioid Analgesics: Morphine and Other Natural Cogeners
239
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
239
Opioid Receptors: Overview
749
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
749
Opioid Analgesics: Synthetic and Semisynthetic Opioids
283
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
283
Nociception
27.9K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.9K
Drug Abuse and Addiction: Pharmacological Phenomena
467
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
467


